Cargando…

Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up

PURPOSE: To report long-term visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) treated with a treat-and-extend regimen (TER) of intravitreal antivascular endothelial growth factor (anti-VEGF) injections in real-world settings. METHODS: Retrospective coho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Javidi, Simon, Dirani, Ali, Antaki, Fares, Saab, Marc, Rahali, Sofiane, Cordahi, Ghassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415083/ https://www.ncbi.nlm.nih.gov/pubmed/32802487 http://dx.doi.org/10.1155/2020/3207614

Ejemplares similares

Treating neovascular age-related macular degeneration in the era of COVID-19
por: Antaki, Fares, et al.
Publicado: (2020)

Displacement of Retained Subretinal Perfluorocarbon Liquid Through Therapeutic Retinal Detachment Induced by Balanced Salt Solution Injection
por: Saab, Marc, et al.
Publicado: (2020)

Revisiting the Utility of Dilated Fundus Exams in Patients with Neovascular Age-Related Macular Degeneration Receiving Regular Intravitreal Injections
por: Antaki, Fares, et al.
Publicado: (2021)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
por: Chandra, Shruti, et al.
Publicado: (2020)

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
por: Parvin, Parmis, et al.
Publicado: (2017)

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen
por: Hirata, Yuki, et al.
Publicado: (2022)

Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration
por: Schroeder, Marion, et al.
Publicado: (2022)

Risk factors for epiretinal membrane formation and peeling following pars plana vitrectomy for primary rhegmatogenous retinal detachment, an OCT guided analysis
por: Szigiato, Andrei-Alexandru, et al.
Publicado: (2022)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

Vitreoretinal Surgery in the Post-Lockdown Era: Making the Case for Combined Phacovitrectomy
por: Antaki, Fares, et al.
Publicado: (2020)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013)

Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat‐and‐extend compared with pro re nata in eyes with neovascular age‐related macular degeneration
por: Aurell, Sandra, et al.
Publicado: (2018)

A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Gemenetzi, Maria, et al.
Publicado: (2017)

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan
por: Cheng, Cheng-Kuo, et al.
Publicado: (2022)

Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
por: Yang, Benjamin Chi-Lan, et al.
Publicado: (2019)

Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy
por: Chen, Yu-Yen, et al.
Publicado: (2019)

Fear Associated with COVID-19 in Patients with Neovascular Age-Related Macular Degeneration
por: Rozon, Jean-Philippe, et al.
Publicado: (2021)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova, Nadezhda P, et al.
Publicado: (2016)

Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice
por: Gurung, Rajya L, et al.
Publicado: (2021)

Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using “Treat and Extend” Regimen
por: Jaki Mekjavic, Polona, et al.
Publicado: (2018)

Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration
por: Lee, Andy, et al.
Publicado: (2020)

Quantitative Optical Coherence Tomography Angiography Biomarkers in a Treat-and-Extend Dosing Regimen in Neovascular Age-Related Macular Degeneration
por: Cabral, Diogo, et al.
Publicado: (2020)

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
por: Jia, Huixun, et al.
Publicado: (2022)

Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD
por: Kamao, Hiroyuki, et al.
Publicado: (2018)

Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis
por: Yin, Xiaobei, et al.
Publicado: (2022)

Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration
por: Jones, Rebecca, et al.
Publicado: (2023)

MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR–TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen
por: Mantel, Irmela, et al.
Publicado: (2019)

Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
por: Ebneter, Andreas, et al.
Publicado: (2020)

External Limiting Membrane Disruption Predicts Long-Term Outcome in Strict Treat-And-Extend Regimen in Neovascular Age-Related Macular Degeneration
por: Hoffmann, Laura, et al.
Publicado: (2021)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Correction to: Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration
por: Jones, Rebecca, et al.
Publicado: (2023)

Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients
por: Ishibashi, Koki, et al.
Publicado: (2021)

High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration
por: Tuerksever, Cengiz, et al.
Publicado: (2021)

Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration
por: Seong, Hyo Jin, et al.
Publicado: (2022)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9l0m0htglnhninv4kqune8f48j